IBRX Earnings Date: Nov 3, 2026 (Estimated) — ImmunityBio, Inc.
NASDAQ · Healthcare · Biotechnology
Updated
When is IBRX's next earnings date?
ImmunityBio, Inc. (IBRX) is expected to report Q3 2026 earnings on Tuesday, November 3, 2026 at 10:00 PM ET (after market close); the date is an estimate and has not been confirmed by the company. The consensus estimate is EPS of -$0.07 on revenue of $59.2M.
How did IBRX do in its last earnings report?
In its most recent report on Aug 4, 2026 (Q2 2026), ImmunityBio, Inc. posted EPS of -$0.08 versus the -$0.08 estimate, a beat of 3.8%. Revenue was $51.2M against a $49.7M estimate. The stock's 1-day post-earnings move was -2.8%.
How much does IBRX stock move after earnings?
IBRX beat EPS estimates in 4 of its last 8 reported quarters. Over the last 8 reports the stock moved an average of 6.6% (up or down) in the day after earnings.
About ImmunityBio, Inc.
ImmunityBio, Inc. is a clinical-stage biotechnology firm, founded in 2014 and based in San Diego, California. The company is focused on developing groundbreaking therapies and vaccines designed to treat a wide array of cancers and infectious diseases. Its innovative approach relies on a comprehensive suite of immunotherapy and cell therapy platforms. These advanced technologies include novel antibody-cytokine fusion proteins, synthetically engineered immunomodulators, cutting-edge vaccine technologies, natural killer (NK) cell therapies, and strategies that harness the adaptive (T-cell) immune system. ImmunityBio currently has several therapeutic candidates in advanced clinical development, with agents undergoing Phase II or III trials. These investigational treatments are aimed at various liquid and solid tumors, such as bladder, pancreatic, and lung cancers, as well as significant infectious pathogens including SARS-CoV-2 and HIV. The company actively engages in strategic partnerships, holding collaboration agreements with esteemed organizations like the National Cancer Institute, the National Institute of Deafness and Communication Disorders, and Amyris, Inc. Additionally, ImmunityBio has secured licensing agreements with numerous entities, including CytRx Corporation, EnGeneIC Pty Limited, GlobeImmune, Inc., Infectious Disease Research Institute, Sanford Health, Shenzhen Beike Biotechnology Co. Ltd., Sorrento Therapeutics, Inc., and Viracta Therapeutics, Inc.
Earnings History
| Date | Period | EPS Est. | EPS Act. | Surprise | Revenue | Result | 1D Δ | 1W Δ | 1M Δ |
|---|---|---|---|---|---|---|---|---|---|
| 2026-08-04 | Q2 2026 | -0.08 | -0.08 | +3.75% | $51.2M | ✅ Beat | -2.80% | +4.76% | +10.07% |
| 2026-05-07 | Q1 2026 | -0.07 | -0.08 | -14.29% | $44.2M | ❌ Miss | -7.40% | -2.74% | -17.42% |
| 2026-02-23 | Q4 2025 | -0.09 | -0.06 | +33.33% | $38.3M | ✅ Beat | +12.99% | +12.41% | +8.05% |
| 2025-11-04 | Q3 2025 | -0.10 | -0.07 | +30.00% | $32.1M | ✅ Beat | +3.37% | +2.88% | +10.58% |
| 2025-08-05 | Q2 2025 | -0.10 | -0.10 | +0.00% | $26.4M | ➖ Inline | +0.00% | +2.49% | -1.66% |
| 2025-03-03 | Q4 2024 | -0.26 | -0.09 | +65.38% | $7.6M | ✅ Beat | -13.37% | -8.81% | -8.51% |
| 2024-08-12 | Q2 2024 | -0.17 | -0.20 | -17.65% | $1.0M | ❌ Miss | -2.64% | -11.67% | -20.26% |
| 2024-03-19 | Q4 2023 | -0.18 | -0.38 | -111.11% | $139,000 | ❌ Miss | +10.31% | -5.71% | -9.58% |
Showing last 8 quarters.
Revenue by segment & region
By segment
Q2 FY26 · $51.2M total
| Segment | Share | Revenue | YoY | Q4 FY24 | Q1 FY25 | Q2 FY25 | Q3 FY25 |
|---|---|---|---|---|---|---|---|
| Product | 98.9% | $50.7M | +91.8% | $8.2M | $16.5M | $26.4M | $31.8M |
| Product and Service, Other | 1.1% | $568K | +14100.0% | $443K | $8K | $4K | $281K |
By region
Q2 FY26 · $51.2M total
| Segment | Share | Revenue | YoY | Q1 FY18 | Q1 FY25 | Q2 FY25 | Q3 FY25 |
|---|---|---|---|---|---|---|---|
| UNITED STATES | 99.0% | $50.7M | +91.9% | — | $16.5M | $26.4M | $31.8M |
| Europe | 1.0% | $518K | — | — | — | — | $262K |
Source: company filings via FMP. YoY compares the same fiscal period a year earlier.